XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
 3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Equity Awards

The following table reflects the activity of RSAs during the thirteen weeks ended March 31, 2023:

Time-basedPerformance-basedMarket-based
SharesWeighted Average
Grant Date Fair Value		SharesWeighted Average
Grant Date Fair Value		SharesWeighted Average
Grant Date Fair Value
Unvested at December 30, 2022464,972 $31.74 335,425 $32.25 333,114 $30.30 
Granted197,345 32.55 713,490 33.16 87,942 28.84 
Vested(161,555)31.82 — — — — 
Forfeited— — — — — — 
Unvested at March 31, 2023500,762 $32.03 1,048,915 $32.87 421,056 $30.00 
The Company granted 998,777 RSAs to its employees at a weighted average grant date fair value of $32.66 during the thirteen weeks ended March 31, 2023. These awards are a mix of time-, market- and performance-based grants that generally vest over a range of periods up to five years. The Company recognized expense totaling $4,790 and $3,043 on its RSAs during the thirteen weeks ended March 31, 2023 and March 25, 2022, respectively.

At March 31, 2023, the total unrecognized compensation cost for unvested RSAs was $37,653 and the weighted-average remaining period was approximately 2.9 years. Of this total, $13,865 related to RSAs with time-based vesting provisions and $23,788 related to RSAs with performance- and market-based vesting provisions. At March 31, 2023, the weighted-average remaining period for time-based vesting and performance-based vesting RSAs were approximately 2.6 years and 3.0 years, respectively.

No share-based compensation expense related to the Company’s RSAs or stock options has been capitalized. As of March 31, 2023, there were 1,542,375 shares available for grant under the 2019 Omnibus Equity Incentive Plan.

The following table summarizes stock option activity during the thirteen weeks ended March 31, 2023:
SharesWeighted
Average
Exercise Price		Aggregate
Intrinsic
Value		Weighted Average
Remaining Contractual
Term (in years)
Outstanding December 30, 2022112,232 $20.23 $1,465 3.2
Exercised— — 
Outstanding March 31, 2023112,232 $20.23 $1,551 2.9
Exercisable at March 31, 2023112,232 20.23 $1,551 2.9

In connection with the CME acquisition, the Company issued stock awards to certain members of the CME management team
which were classified as liabilities. These awards vest over a period of up to four years. Stock-based compensation expense for
these awards was $544 and $0 during the thirteen weeks ended March 31, 2023 and March 25, 2022, respectively. The fair value of these awards was $906 and $362 as of March 31, 2023 and December 30, 2022, respectively, and is presented within Other liabilities and deferred credits on the Company’s condensed consolidated balance sheets.